Total revenues for the quarter ended at MNOK 109.8 (MNOK 82.5) and includes MNOK 5.3 granted by the U.S. Paycheck Protection Program related to COVID-19. Total revenues for the first half ended at MNOK 212.4 (185.6).
Sales revenues for the quarter ended at MNOK 104.5 (MNOK 82.5), an increase of 26.7%. This is a new record for sales in any quarter. Currency neutral growth in sales of own products was 40.2%. Sales revenues for the first half ended at MNOK 207.1 (MNOK 185.6), an 11.6% increase.
Operating profit (EBIT) for the quarter ended at MNOK 42.7 (MNOK 27.7), a 54.0% increase and by far the best EBIT for a quarter ever. Operating profit for the first half ended at MNOK 71.7 (MNOK 52.5), a 36.7% increase. This is the best operating profit for the first half ever.
High growth in number of procedures in the USA with 50% as well as consumable probe sales growth with 35%, reflect an increasing number of surgeries being performed and continuing recovery from the COVID pandemic.
Medistim added the Pay Per Procedure (PPP) business model to the MiraQ™ system generation to U.S. customers in the second quarter.
A dividend of NOK 3.00 per share, a total of MNOK 54.6, was paid in the second quarter.